STOCK TITAN

IM Cannabis Provides Corporate Update

(Very High)
(Neutral)
Tags

IM Cannabis (Nasdaq: IMCC) announced that Mr. Alon Dayan has resigned from its board of directors for personal reasons. The board and management thanked him for his contributions and wished him well. IM Cannabis operates a medical cannabis platform in Israel and Germany, including import, distribution and retail pharmacy activities.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

Market Context

The active F-3 resale registration dated June 9, 2026 covers up to 17,276,931 shares, and the compan...
Analysis

The active F-3 resale registration dated June 9, 2026 covers up to 17,276,931 shares, and the company will not receive resale proceeds. This provides financing context for the director resignation; subsequent filings may clarify whether board composition changes further.

Key Figures

Announcement date: July 27, 2026
1 metrics
Announcement date July 27, 2026 Corporate update publication

Historical Context

5 past events · Latest: Jul 01 (Negative)
Pattern 5 events
Date Event Sentiment 24h Move Catalyst
Jul 01 Convertible note financing Negative -1.4% Convertible note financing with repayment in shares and accompanying warrants
Jun 18 European asset sale Positive -16.5% Non-binding sale expected to reduce debt by approximately C$10.5 million
Jun 09 Resale registration Negative -8.7% Form F-3 covered 17,276,931 shares for selling shareholders
Jun 03 Convertible note financing Negative +1.8% Convertible note financing included warrants and repayment in common shares
May 13 First-quarter earnings Negative -3.3% Quarterly results reported revenue of $8.7 million and a $2.5 million net loss

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent IMCC announcements produced mostly negative reactions, including financing, resale-registration, asset-sale, and earnings disclosures.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

TORONTO and GLIL YAM, Israel, July 27, 2026 /PRNewswire/ -- IM Cannabis Corp. ("IMCor the "Company") (Nasdaq: IMCC), a medical cannabis company with operations in Israel and Germany, announces that Mr. Alon Dayan has resigned as a director of the Company for personal reasons.

IM Cannabis Logo

The board of directors and management of IM Cannabis thank Mr. Dayan for his service and valuable contributions to the Company during his tenure and extend their best wishes to him in his future endeavours.

About IM Cannabis Corp.

IMC (Nasdaq: IMCC) is an international company focused on building and scaling innovative businesses and technologies across global markets. The Company currently operates a medical cannabis platform serving patients in Israel and Germany while evaluating opportunities to expand into additional technology-driven sectors.

The IMC ecosystem operates in Israel through its subsidiaries, which import and distribute cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies and online platforms, in Israel that enable the safe delivery and quality control of IMC products throughout the entire value chain. In Germany, the IMC ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients.

Company Contact:

Michal Efraty
Investor & Public Relations
IM Cannabis Corp.
michal@efraty.com

Oren Shuster, Chief Executive Officer
IM Cannabis Corp.
info@imcannabis.com

Disclaimer for Forward-Looking Statements

This press release contains forward-looking information and forward-looking statements within the meaning of applicable Canadian securities laws and, where applicable, United States securities laws. Forward-looking statements in this press release include, but are not limited to, statements regarding the Company's evaluation of opportunities to expand into additional technology-driven sectors and the Company's business focus, strategy and future opportunities.

Forward-looking statements are based on the beliefs, expectations and assumptions of management as of the date of this press release, including assumptions regarding the Company's ability to continue operating its medical cannabis platform in Israel and Germany, the availability of opportunities that are consistent with the Company's business strategy, the Company's ability to evaluate and pursue such opportunities, market conditions, regulatory conditions and the continued availability of required licences, permits and approvals.

Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or developments to differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among others, risks relating to the highly regulated nature of the medical cannabis industry, the Company's ability to maintain applicable licences, permits and regulatory approvals, changes in applicable laws, regulations and enforcement practices, market and business conditions in Israel and Germany, the availability and suitability of strategic opportunities, the Company's liquidity and capital resources, and the risks described under the heading "Risk Factors" in the Company's most recent annual report and other continuous disclosure documents filed on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov.

Readers are cautioned not to place undue reliance on forward-looking statements. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any obligation to update or revise any forward-looking statements, except as required by applicable securities laws.

Logo - https://mma.prnewswire.com/media/1742228/IM_Cannabis_Logo.jpg

Cision View original content:https://www.prnewswire.com/news-releases/im-cannabis-provides-corporate-update-302835344.html

SOURCE IM Cannabis Corp.

FAQ

What corporate change did IM Cannabis (IMCC) announce on July 27, 2026?

IM Cannabis announced that director Alon Dayan resigned from the company’s board for personal reasons. According to IM Cannabis, the board and management expressed appreciation for his service and extended best wishes for his future endeavours.

Why did Alon Dayan resign from the IM Cannabis (IMCC) board of directors?

IM Cannabis stated that Alon Dayan resigned for personal reasons. According to IM Cannabis, no further details were provided, and the company focused its statement on thanking him for his service and valuable contributions during his tenure on the board.

How does IM Cannabis (IMCC) describe its business operations in Israel and Germany?

IM Cannabis describes itself as operating a medical cannabis platform serving patients in Israel and Germany. According to IM Cannabis, it imports and distributes cannabis, runs medical cannabis retail pharmacies and online platforms in Israel, and distributes cannabis to pharmacies in Germany through Adjupharm GmbH.

What role do IM Cannabis subsidiaries play in the company’s Israel operations (IMCC)?

In Israel, IM Cannabis operates through subsidiaries that import and distribute cannabis to medical patients. According to IM Cannabis, these activities leverage proprietary data and patient insights and include medical cannabis retail pharmacies and online platforms to support safe delivery and quality control.

How does IM Cannabis (IMCC) conduct its medical cannabis business in Germany?

In Germany, IM Cannabis operates through Adjupharm GmbH, which distributes cannabis to pharmacies for medical patients. According to IM Cannabis, this German operation is part of its broader international medical cannabis platform focused on serving regulated medical markets.

Is IM Cannabis (IMCC) focused only on cannabis or also on other sectors?

IM Cannabis describes itself as an international company focused on building and scaling innovative businesses and technologies across global markets. According to IM Cannabis, it currently operates a medical cannabis platform while evaluating opportunities to expand into additional technology-driven sectors.